Resistant Hypertension Market Primed for 5% Annual Growth During 2020-2034 Due to Rising Diagnosis and Treatment of Patients with Resistant Hypertension, along with Approvals and Developments of Novel Treatments as Perceived by DelveInsight
New Treatments for Treatment-Resistant Hypertension on the Horizon
A recent report on the treatment-resistant hypertension (TRH) market offers insights into emerging therapies and market dynamics, providing a comprehensive analysis for the study period 2020-2034 in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The report segments the diagnosed prevalence of TRH into total, gender-specific, and age-specific cases, revealing that the diagnosed prevalence ranges from 10-14% across the 7MM. In the US, the highest diagnosed prevalence was observed in adults aged 60 and above in 2024.
Several promising TRH therapies are in advanced clinical development, addressing pathways such as endothelin receptor antagonism and aldosterone synthesis blockade.
Currently Available Treatment: Aprocitentan
One such therapy, Aprocitentan, a dual endothelin receptor antagonist, was FDA-approved in March 2024. It has demonstrated significant blood pressure reductions when added to a 3-drug regimen in resistant hypertension patients.
Promising Therapies in Development: Baxdrostat and RTN-001
Baxdrostat, a selective aldosterone synthase inhibitor, is a new drug class targeting aldosterone dysregulation. It met primary and secondary endpoints in a Phase III trial in 2025, showing efficacy in uncontrolled or resistant hypertension. No exact US launch date has been announced, but it is in late-stage development with positive trial results as of mid-2025.
RTN-001 from Retension Pharmaceuticals is a once-daily, modified-release formulation designed for sustained 24-hour blood pressure control aimed at treatment-resistant hypertension. It is expected to start a Phase 2b trial in Q4 2025, enrolling about 280 patients across multiple US sites. Commercial launch would presumably follow successful Phase 3 studies and regulatory approval, likely not before 2027.
Upcoming Entrants: Baxdrostat from AstraZeneca and Lorundrostat from Mineralys Therapeutics
AstraZeneca's Baxdrostat and Mineralys Therapeutics' Lorundrostat are anticipated to enter the US market by 2026.
The assessment of resistant hypertension involves confirming the accuracy of blood pressure readings and ruling out the white coat effect using validated out-of-office monitoring methods, such as automated office blood pressure (AOBP) measurement.
The treatment-resistant hypertension market is projected to grow due to rising uncontrolled hypertension, increased awareness, improved diagnostics, and innovations in combination therapies and device-based interventions. The market report includes a scope that covers therapeutic assessment, treatment-resistant hypertension market dynamics, competitive intelligence analysis, unmet needs, KOL's views, treatment-resistant hypertension market access and reimbursement.
Leading companies developing emerging TRH therapies include AstraZeneca, Mineralys Therapeutics, E-Star BioTech, Ionis Pharmaceuticals, Kardigan, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Roche, and others. The report provides insights into the historical and current treatment-resistant hypertension patient pool and forecasted trends for the 7MM, recognizing the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The market size for treatment-resistant hypertension was found to be USD 6.8 billion in the 7MM in 2024. The treatment resistant hypertension market report is available for download at Treatment Resistant Hypertension Market Report.
[1] Source: [Link to the source] [2] Source: [Link to the source] [3] Source: [Link to the source] [4] Source: [Link to the source] [5] Source: [Link to the source]
- Cloud-based software solutions for monitoring medical-conditions like treatment-resistant hypertension could potentially revolutionize health-and-wellness, improving the accuracy of out-of-office blood pressure readings and thereby aiding in the earlier detection of cardiovascular-health risks.
- Amidst the array of new TRH therapies, the science behind endothelin receptor antagonism, as exemplified by Aprocitentan, has demonstrated remarkable performance in reducing blood pressure in treatment-resistant hypertension patients.
- In the ever-evolving landscape of science and medical-advancements, the emergence of new treatments for treatment-resistant hypertension, such as Baxdrostat and RTN-001, represents a significant leap forward in medicine, particularly in addressing uncontrolled or resistant hypertension in various age groups.
